Cogent Biosciences, Inc. (COGT)

Cogent Biosciences, Inc. is trading at $38.07, up 0.53% on the session. The 50 day average sits at $37.82 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 44.7, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $37.40 with resistance near $40.09, so that band frames the current range. Average daily movement is roughly $1.95, or about 5.1% of the share price, which is what any stop placement has to allow for. The overall health score of 52 out of 100 combines a trend score of 72, momentum of 32 and a risk score of 48.

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.